14-day Premium Trial Subscription Sign Up For FreeGet Free

ARCA biopharma Stock Forecast NASDAQ:ABIO

$2.43 (-6.90%)

Volume: 428k

Closed: Nov 29, 2021

Hollow Logo Score: -3.124

ARCA biopharma Stock Forecast

$2.43 (-6.90%)

Volume: 428k

Closed: Nov 29, 2021

Score Hollow Logo -3.124
Which way will ABIO go? Request
Key Stats
Beta 0.76
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 40 and the stock is currently not being overbought or oversold

ARCA biopharma stock price took a fall of -6.90% on Monday
(Updated on Nov 29, 2021)

Sell candidate since 2021-11-26 Loss -6.90%

The ARCA biopharma stock price fell by -6.90% on the last day (Monday, 29th Nov 2021) from $2.61 to $2.43. During the day the stock fluctuated 9.24% from a day low at $2.38 to a day high of $2.60. The price has been going up and down for this period, and there has been a -1.62% loss for the last 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -96 thousand shares and in total, 428 thousand shares were bought and sold for approximately $1.04 million.

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -22.84% during the next 3 months and, with a 90% probability hold a price between $1.68 and $2.00 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

A buy signal was issued from a pivot bottom point on Monday, November 22, 2021, and so far it has risen 8.97%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The ARCA biopharma stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term moving average at $2.59. On a fall, the stock will find some support from the short-term average at $2.38. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

Support, Risk & Stop-loss

ARCA biopharma finds support from accumulated volume at $2.41 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day, but be aware of low or falling volume as this increases the risk. During the last day, the stock moved $0.22 between high and low, or 9.24%. For the last week the stock has had a daily average volatility of 9.43%.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is ARCA biopharma stock A Buy?

ARCA biopharma holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Sell candidate.

Current score: -3.124

Predicted Opening Price for ARCA biopharma of Tuesday, November 30, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price November 30, 2021 Current price
$2.47 $2.43 (Undervalued)
Sell Candidate Downgraded

Remember To Visit Our YouTube Channel

Volatility and Risk
Daily Average Volatility: 9.43 %
Overall Risk: Very High High Medium Low Very Low
9.43 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $2.61
Price: $2.43
Support: $2.41

ABIO Insider Trading Show all Trades



Last 100 transactions
Buy: 1 276 856 | Sell: 16 170 490 (Shares)
Date Action Amount Person Type
Nov 22, 2021 Buy 50 000 Ozeroff Christopher David Common Stock
May 12, 2021 Buy 10 000 Conway Robert E Common Stock
May 05, 2021 Buy 10 000 Conway Robert E Common Stock
Jan 12, 2021 Buy 12 000 Grais Linda Stock Option (right to buy)
Jan 12, 2021 Buy 12 000 Woosley Raymond L. Stock Option (right to buy)
Show all Insider Trades


Last 100 transactions
Buy: 1 276 856 | Sell: 16 170 490 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 2.69 10.70 %
2.61 7.24 %
2.55 5.10 %
Current price: 2.43
Support 2.39 -1.81 %
2.33 -3.95 %
2.25 -7.41 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 2.74 12.76 %
2.70 11.11 %
2.61 7.41 %
Current price 2.43
Support 2.41 -0.82%
2.30 -5.35%
2.23 -8.23%

Click to get the best stock tips daily for free!

About ARCA biopharma

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in patients with heart failure and left ventricular with reduced left ventricular ejection fraction. The company also engages in developing recombinant Nem... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE